Qudexy Capsule, Extended Release
Product Images NDC 0245-1073

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Qudexy (NDC 0245-1073). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Qudexy 01)

Chemical structure diagram of Topiramate, the active ingredient in QUDEXY XR extended-release capsules. The structure shows characteristic functional groups, including sulfonamide, ether, and isopropyl moieties.*

FDA Label Image

Figure 1 (Qudexy 02)

Kaplan-Meier curve showing cumulative rates for time to first seizure over up to 500 days in subjects treated with Topiramate at doses of 50 mg/day and 400 mg/day. The graph compares seizure occurrence over time between the two dosage groups with a p-value of 0.0002, indicating statistical comparison.*

FDA Label Image

Figure 2 (Qudexy 03)

A bar chart comparing the proportion of patients experiencing different percentage ranges of reduction in seizure frequency from baseline between placebo and QUDEXY XR 200 mg/day. The x-axis shows seizure reduction ranges (Worse, 0 to <25%, 25 to <50%, 50 to <75%, 75 to 100%), and the y-axis shows the proportion of patients in percent. Placebo and QUDEXY XR groups are represented with separate bars for each range.*

FDA Label Image

Figure 3 (Qudexy 04)

A bar chart showing the change from baseline to double-blind phase in average monthly migraine period rate (±SE) for placebo and topiramate at doses of 50 mg/day, 100 mg/day, and 200 mg/day. Data is presented for two studies, labeled Study 11 and Study 12, with markers indicating statistical significance at p<0.010 and p<0.001 levels.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Label for QUDEXY XR 25 mg extended-release capsules containing topiramate, packaged in a 30-capsule bottle. The label indicates once-daily dosing, provides storage instructions, and lists Upsher-Smith Laboratories, LLC as the distributor.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Label for Qudexy XR 50 mg extended-release capsules (topiramate) by Upsher-Smith Laboratories, LLC. The label includes the dosage form, strength, NDC 0245-1072-30, package count of 30 capsules, storage instructions, and a barcode. It advises once-daily dosing and instructs pharmacists to dispense a separate medication guide.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Label for QUDEXY XR 100 mg extended-release capsules containing topiramate. The oral medication is supplied in a bottle of 30 capsules by Upsher-Smith Laboratories, LLC. The label includes dosing instructions, storage conditions, and a barcode along with branding and regulatory information.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

Label for QuDexy XR (topiramate) extended-release capsules, 150 mg strength. The label indicates once-daily dosing and contains 30 capsules. The product is distributed by Upsher-Smith Laboratories, LLC, Maple Grove, MN. It includes storage instructions and a pharmacist dispensing notice. The label features the Upsher-Smith logo and relevant regulatory and packaging information.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Label for QUDEXY XR (topiramate) extended-release capsules, 200 mg strength, by Upsher-Smith Laboratories, LLC. The label shows the product name, dosage form as extended-release capsules, quantity of 30 capsules, and dosing information to take once daily. It includes storage instructions, distributor details, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.